Is Cynata Therapeutics Ltd halal to invest in?

According to Musaffa's Shariah screening methodology, Cynata Therapeutics Ltd (CYP.AX) is currently classified as HALAL as of July 2025. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Cynata Therapeutics Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Cynata Therapeutics Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of Cynata Therapeutics Ltd?

Muslim investors may consider investing in Cynata Therapeutics Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Cynata Therapeutics Ltd classified as HALAL?

Musaffa determines the Shariah status of Cynata Therapeutics Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Cynata Therapeutics Ltd updated?

The Shariah compliance status of Cynata Therapeutics Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Cynata Therapeutics Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Cynata Therapeutics Ltd?

You can check the latest Shariah compliance status of Cynata Therapeutics Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

CYP.AX Shariah Compliance

Screening Methodology: AAOIFI

HALAL

Last Updated: July 31, 2025

Report Source: 2025 2nd Quarter Report

Cynata Therapeutics Ltd. Stock Analysis CYP.AX

Australia Health Care Micro Cap Report: Q2, 2025

Cynata Therapeutics Ltd. engages in the development and commercialization of therapeutic products. The firm is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells (iPSCs) to manufacture cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale. Its product candidates include CYP-001, CYP-004 and CYP-006TK. CYP-001 is under Phase II clinical trials with a focus on treatment for steroid-resistant acute graft versus host disease (GvHD) and a Phase 1/II trial in patients undergoing kidney transplantation. CYP-006TK is a Cymerus iPSC-derived MSC topical wound dressing product candidate. This product is used in the Company’s Phase I clinical trial in diabetic foot ulcers (DFU). CYP-004, is an iPSC-derived MSC product for intra-articular injection (injection into a joint), is ongoing with a Phase III trial in patients with osteoarthritis of the knee.

Key Statistics of Cynata Therapeutics Ltd (CYP.AX)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

AUD0.32AUD0.33

Today's Open

AUD0.33

Volume

344.59K

P/E Ratio (TTM)

52 Week Range

AUD0.15AUD0.44

Market Cap

75.99M

Avg. Volume

37.06K

Dividend Yield

Financial Metrics & Statements of Cynata Therapeutics Ltd (CYP.AX)

FAQ's for Cynata Therapeutics Ltd (CYP.AX)

According to Musaffa’s Shariah screening methodology, Cynata Therapeutics Ltd (CYP.AX) is currently classified as HALAL as of July 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.